Neurotrophic Keratitis

Dompé’s cenegermin selected by FDA for new national priority review program

The U.S. Food and Drug Administration has selected cenegermin, developed by Dompé, as 1 of 9 therapies to receive a Commissioner’s National Priority Voucher (CNPV), a new program that accelerates review of products addressing significant unmet medical needs. Cenegermin (Oxervate), the first FDA-approved therapy for neurotrophic keratitis, was recognized for...